Evidence map›Paper›PMID 35831837›Full record

ArticleBMC cancer2022

Impact of pectoralis muscle loss on cardiac outcome and survival in Cancer patients who received anthracycline based chemotherapy: retrospective study.

Wael Toama, Jason Wiederin, Ryan Shanley, Patricia Jewett, Christina Gu, Chetan Shenoy, Prabhjot S Nijjar, Anne H Blaes

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.1field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 3 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Wael ToamaDivision of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, MMC 480, 14-142E Phillips-Wangensteen Bldg, Minneapolis, MN, 55455, USA. Toama002@umn.edu.
Jason WiederinDepartment of Medicine, Hennepin Healthcare, Minneapolis, MN, USA.
Ryan ShanleyUniversity of Minnesota Masonic Cancer Center, Biostatistics Core, Minneapolis, MN, USA.
Patricia JewettDivision of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, MMC 480, 14-142E Phillips-Wangensteen Bldg, Minneapolis, MN, 55455, USA.
Christina GuUniversity of Minnesota Medical School, Minneapolis, MN, USA.
Chetan ShenoyDivision of Cardiology, University of Minnesota, Minneapolis, MN, USA.
Prabhjot S NijjarDivision of Cardiology, University of Minnesota, Minneapolis, MN, USA.
Anne H BlaesDivision of Hematology, Oncology and Transplantation, University of Minnesota, 420 Delaware Street SE, MMC 480, 14-142E Phillips-Wangensteen Bldg, Minneapolis, MN, 55455, USA.
University of Minnesota · USHennepin Healthcare Research Institute · USUniversity of Minnesota Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe impact of pectoralis muscle mass index (PMI) on cardiac events is not well studied in cancer patients, especially in those who have received chemotherapy with high potential cardiac toxicity such as anthracyclines.

methodsIndividuals aged ≥18 years with a diagnosis of breast cancer, sarcoma, or lymphoma who received anthracycline-based chemotherapy at the University of Minnesota MHealth Fairview between 2009 and 2014. Eligible patients had to have two CT scans: a baseline CT scan within 6 months prior to chemotherapy and a follow-up CT scan within 2 years after treatment. The PMI was calculated as the right pectoralis muscle area indexed to height squared. Multivariable linear regression was used to analyze factors associated with PMI at follow-up, overall mortality, and major cardiac events (MACE).

resultsA total of 474 patients (breast cancer 192; lymphoma 184; sarcoma 98) participated with a median age of 61 years at the time of baseline CT scan; 161 (34%) were male. Almost all patients received anthracyclines except 12% who received trastuzumab only. The median baseline PMI was 5.8 cm

conclusionGreater pre-treatment pectoralis muscle index in patients treated with anthracyclines have a lower risk of MACE. Early identification of sarcopenia using PMI could trigger proactive engagement for intervention and risk-stratified therapies.

Indexed as

Breast NeoplasmsSarcomaAdolescentAdultAnthracyclinesAntibiotics, AntineoplasticFemaleHumansMaleMiddle AgedPectoralis MusclesRetrospective StudiesAnthracyclinesAntibiotics, AntineoplasticBreast cancerCardiacLymphomaSarcomaSarcopenia

Identifiers

PMID35831837
PMCPMC9281070
OpenAlexW4285394336

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.